Latest News and Press Releases

Science 37 announces the successful completion of its third FDA inspection with a No Action Indicated (NAI) categorization.

Science 37 and Catalent announce a strategic partnership enabling direct-to-patient investigational medicinal product (IMP) delivery for clinical research.

Science 37 announces the successful completion of its second FDA inspection, reaffirming the quality of its Direct-to-Patient Site for clinical research.

Science 37 announces the appointment of Tyler Van Horn as Chief Executive Officer.

Science 37 contributes almost half (47%) of the U.S. enrollment for GSK Phase 3 rare disease study while bolstering participant retention figures.

MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Today, Science 37, a leader in enhancing patient access to clinical trials, announced that it has received Frost & Sullivan’s 2024 Global...

Science 37 opens new, state-of-the-art facility, to enhance collaboration and improve patient recruitment and study support for clinical trials.

Science 37 enrolls 65 patients per month for its sponsor's Phase 3 infectious disease clinical trial.

Nearly 20 studies have successfully leveraged Science 37's medical and operational expertise to boost patient recruitment and enrollment activities.

Science 37, a leader in enhancing patient access to clinical trials, surpasses enrollment targets and helps accelerate Phase 2 rare disease study.